Does BINIMETINIB Cause Second primary malignancy? 74 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 74 reports of Second primary malignancy have been filed in association with BINIMETINIB (MEKTOVI). This represents 1.1% of all adverse event reports for BINIMETINIB.
74
Reports of Second primary malignancy with BINIMETINIB
1.1%
of all BINIMETINIB reports
6
Deaths
25
Hospitalizations
How Dangerous Is Second primary malignancy From BINIMETINIB?
Of the 74 reports, 6 (8.1%) resulted in death, 25 (33.8%) required hospitalization, and 2 (2.7%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BINIMETINIB. However, 74 reports have been filed with the FAERS database.
What Other Side Effects Does BINIMETINIB Cause?
Off label use (902)
Death (719)
Nausea (657)
Fatigue (562)
Diarrhoea (521)
Product use in unapproved indication (508)
Pyrexia (490)
Neoplasm progression (387)
Vomiting (375)
Rash (360)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which BINIMETINIB Alternatives Have Lower Second primary malignancy Risk?
BINIMETINIB vs BIOFLAVONOIDS
BINIMETINIB vs BIOTIN
BINIMETINIB vs BIPERIDEN
BINIMETINIB vs BIRCH TRITERPENES
BINIMETINIB vs BISACODYL